1. Home
  2. OSPN vs RIGL Comparison

OSPN vs RIGL Comparison

Compare OSPN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneSpan Inc.

OSPN

OneSpan Inc.

N/A

Current Price

$22.15

Market Cap

946.7M

Sector

Technology

ML Signal

N/A

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

N/A

Current Price

$39.76

Market Cap

911.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OSPN
RIGL
Founded
1991
1996
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
946.7M
911.8M
IPO Year
2000
2000

Fundamental Metrics

Financial Performance
Metric
OSPN
RIGL
Price
$22.15
$39.76
Analyst Decision
Hold
Buy
Analyst Count
4
4
Target Price
$23.50
★ $64.40
AVG Volume (30 Days)
★ 897.0K
204.0K
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 2.30%
N/A
EPS Growth
28.77
★ 1867.68
EPS
0.68
★ 1.97
Revenue
$243,180,000.00
★ $294,282,000.00
Revenue This Year
$5.28
$5.32
Revenue Next Year
$2.44
$24.14
P/E Ratio
$33.19
★ $21.00
Revenue Growth
N/A
★ 64.15
52 Week Low
$10.07
$24.84
52 Week High
$27.45
$52.61

Technical Indicators

Market Signals
Indicator
OSPN
RIGL
Relative Strength Index (RSI) 53.32 34.58
Support Level $21.29 $37.60
Resistance Level $27.45 $43.74
Average True Range (ATR) 1.13 2.72
MACD -0.20 -0.62
Stochastic Oscillator 16.78 15.98

Price Performance

Historical Comparison
OSPN
RIGL

About OSPN OneSpan Inc.

OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Share on Social Networks: